ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P.

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PT.

A live audio webcast will be available under Events & Webcasts in the company investor website and an archived webcast will be posted after the event.

Argus Jan 5 session

+0.84% close to close Open Argus

Details

News Market Reaction – ADMA

On Jan 5, the day this news came out, ADMA closed 0.84% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Key Figures

Conference date: January 12, 2026 Presentation time: 9:45 a.m. PT

Conference date

January 12, 2026

J.P. Morgan Healthcare Conference presentation

Presentation time

9:45 a.m. PT

J.P. Morgan Healthcare Conference session

Historical Context

4 past events · Latest: Nov 05

4 events

1. Nov 05

   Q3 2025 earnings

   24h Move

   +5.1%

   Strong Q3 revenue, net income and raised multi-year guidance with margin drivers.

2. Oct 29

   Earnings call schedule

   24h Move

   -0.3%

   Announcement of Q3 2025 results date and accompanying conference call details.

3. Aug 06

   Q2 2025 earnings

   24h Move

   -9.7%

   Strong Q2 growth, yield enhancement start, refinancing and long-term revenue outlook.

4. Jul 30

   Earnings call schedule

   24h Move

   +1.8%

   Scheduling second quarter 2025 results release and webcast for investors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.

A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM^® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ADMA (ADMA) present at the J.P. Morgan Healthcare Conference in 2026?

ADMA will present on Monday, January 12, 2026 at 9:45 a.m. PT.

Who is presenting for ADMA (ADMA) at the January 12, 2026 J.P. Morgan Healthcare Conference?

Adam Grossman, President and Chief Executive Officer, will deliver the podium presentation.

How can investors access ADMA's January 12, 2026 J.P. Morgan presentation?

A live audio webcast will be available via the Events & Webcasts page on the company's investor website.

Will ADMA (ADMA) provide a replay of the January 12, 2026 presentation?

Yes. An archived webcast will be posted on the company's investor website after the event.

Where is the ADMA webcast for the January 12, 2026 presentation hosted?

The webcast is hosted on ADMA's investor site under https://ir.admabiologics.com/events-webcasts.